Metagenomi Therapeutics (MGX) Net Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Net Margin of 1847.68% for Q1 2026, down 124096.0% year-over-year from N/an in Q1 2025, and down 220.77% quarter-over-quarter from 576.02% in Q4 2025.
Metagenomi Therapeutics (MGX) Net Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Net Margin for 4 consecutive years, with 1847.68% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 124096.0% year-over-year to 1847.68%; the TTM figure through Mar 2026 stood at 384.61% (down 21240.0% YoY), while the FY2025 annual figure was 348.54%, down 19928.0% from the prior year.
- Net Margin eased to 1847.68% in Q1 2026 per MGX's latest filing, from 576.02% in the prior quarter.
- Across five years, Net Margin topped out at 53.67% in Q2 2024 and bottomed at 1847.68% in Q1 2026.
- Historically, Net Margin has averaged 369.4% across 4 years, with a median of 225.36% in 2024.
- Annual changes were most pronounced in 2024 — Net Margin surged 6107 bps — and 2026, when it sank 124096 bps.
- Metagenomi Therapeutics' Net Margin stood at 155.61% in 2023, then tumbled by 56 bps to 243.37% in 2024, then sank by 137 bps to 576.02% in 2025, then slumped by 221 bps to 1847.68% in 2026.
- Business Quant data shows MGX's Net Margin at 1847.68% in Q1 2026, 576.02% in Q4 2025, and 235.51% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,847.68% |
| Dec 31, 2025 | -576.02% |
| Sep 30, 2025 | -235.51% |
| Jun 30, 2025 | -233.85% |
| Mar 31, 2025 | -606.71% |
| Dec 31, 2024 | -243.37% |
| Sep 30, 2024 | -163.04% |
| Jun 30, 2024 | -53.67% |
| Mar 31, 2024 | -225.36% |
| Dec 31, 2023 | -155.61% |
| Sep 30, 2023 | -160.32% |
| Jun 30, 2023 | -114.74% |
| Mar 31, 2023 | -186.36% |